🇺🇸 FDA
Pipeline program

RESTEN-MP

AVI-4126-17

Phase 2 small_molecule completed

Quick answer

RESTEN-MP for Coronary Artery Disease is a Phase 2 program (small_molecule) at Sarepta Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Coronary Artery Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials